Sign In  |  Register  |  About San Anselmo  |  Contact Us

San Anselmo, CA
September 01, 2020 1:33pm
7-Day Forecast | Traffic

  • Search Hotels in San Anselmo

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Summit Therapeu ADR (NQ: SMMT )

19.00 +0.58 (+3.18%)
Streaming Delayed Price Updated: 12:21 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 587,288
Open 18.50
Bid (Size) 18.99 (6)
Ask (Size) 19.02 (2)
Prev. Close 18.42
Today's Range 18.50 - 19.19
52wk Range 1.890 - 33.89
Shares Outstanding 97,381,774
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Summit Therapeutics Inc.
Via Business Wire
Merck Spends Up To $3.3 Billion In An Insurance Policy Against Summit Therapeutics
Merck is spending up to $3.3 billion in a licensing deal for an anti-PD-1/VEGF drug from China. 
Via Investor's Business Daily

Performance

YTD
+619.89%
+619.89%
1 Month
-7.70%
-7.70%
3 Month
+40.57%
+40.57%
6 Month
+339.93%
+339.93%
1 Year
+874.62%
+874.62%

More News

Read More
BioNTech Earns Upgrade From Goldman Sachs As Investment Thesis Shifts Toward Cancer Potential
Via Benzinga
MarketBeat Week in Review – 11/4 - 11/8
Via MarketBeat
Topics Economy Government
Exposures Interest Rates Political
Preview: Summit Therapeutics's Earnings
Via Benzinga
(SMMT) - Analyzing Summit Therapeutics's Short Interest
Via Benzinga
2 Hot Biopharma Stocks to Buy and Hold for 5 Years
Via The Motley Fool
Why Summit Therapeutics Stock Was a Winner Today
Via The Motley Fool
Summit Therapeutics 'Unique Investment In Oncology,' Lead Drug Candidate Shows Promise Over Keytruda And Opdivo
Via Benzinga
Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Via MarketBeat
Exposures Product Safety
This Tencent Music Entertainment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Via Benzinga
3 Magnificent Stocks Under $100 to Buy in November
Via The Motley Fool
2 Dividend Stocks to Buy for a Lifetime of Passive Income
Via The Motley Fool
3 Stocks That Have Generated 1,000% Returns in Just 2 Years
Via The Motley Fool
Summit Therapeutics Reports Operational Progress and Financial Results for the Third Quarter and Nine Months Ended September 30, 2024
From Summit Therapeutics Inc.
Via Business Wire
From Nuvalent to Nuvectis Pharma: New Report Highlights NXP900's Synergy in NSCLC and Anticipated NXP800 Data Update
Via News Direct
Is Summit Therapeutics a Millionaire Maker?
Via The Motley Fool
Up Over 600% in 2024, Can Summit Therapeutics Stock Keep Rising?
Via The Motley Fool
Billionaire Bob Duggan Snags $33M Miami Penthouse Amid Summit Therapeutics 689% Stock Rally
Via Benzinga
Summit Therapeutics to Host Third Quarter 2024 Financial Results & Operational Progress Call on October 30, 2024
From Summit Therapeutics Inc.
Via Business Wire
Billionaire Israel Englander Just Quietly Took a Stake in This Potentially Lucrative Pharmaceutical Stock. Should You?
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Up 700% This Year, Is It Too Late to Invest in This Stock?
Via The Motley Fool
Better Biotech Stock to Buy With $1,500 Right Now: Viking Therapeutics vs. Summit Therapeutics
Via The Motley Fool
3 Things You Need to Know If You Buy Summit Therapeutics Stock Today
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanAnselmo.com & California Media Partners, LLC. All rights reserved.